• LAST PRICE
    0.4100
  • TODAY'S CHANGE (%)
    Trending Down-0.0076 (-1.8199%)
  • Bid / Lots
    0.4000/ 30
  • Ask / Lots
    0.4200/ 13
  • Open / Previous Close
    0.4020 / 0.4176
  • Day Range
    Low 0.3960
    High 0.4200
  • 52 Week Range
    Low 0.3790
    High 0.7487
  • Volume
    35,614
    below average

Search Criteria

Filter search criteria using below inputs

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
CompanyCountrySymbol
Select an index
Price Comparison Graph. See accessible table below
1 Day Comparison Chart Accessibility Table. Friday's close: 0.4176
TimeVolumeAIM
09:32 ET44000.403
09:37 ET1000.410101
09:39 ET15000.414949
09:50 ET21000.4036
09:51 ET4000.416447
09:53 ET4000.419999
09:55 ET11190.4021
09:57 ET3000.4199
10:04 ET10000.42
10:09 ET4000.411
10:11 ET121920.4
10:13 ET7620.4144
10:51 ET75000.41
11:14 ET11800.42
11:36 ET1000.41
12:08 ET2460.42
12:35 ET2500.41
12:48 ET5460.41
Data delayed at least 15 minutes.
Industry Peers Overview Table
Company sortableMarket Cap sortableP/E Ratio (TTM) sortableEPS Growth (5yr) sortable
United StatesAIM
AIM ImmunoTech Inc
20.4M
-1.0x
---
United StatesPPBT
Purple Biotech Ltd
20.2M
-0.7x
---
United StatesNCNA
NuCana PLC
16.4M
-0.4x
---
United StatesBIOR
Biora Therapeutics Inc
20.1M
-0.1x
---
United StatesCUBT
Curative Biotechnology Inc
20.8M
-3.2x
---
United StatesLABP
Landos Biopharma Inc
19.6M
-1.7x
---
As of 2024-02-26

Company Information

AIM ImmunoTech Inc. is an immuno-pharmaceutical company. The Company is focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders and viral diseases, including COVID-19. The Company’s flagship products are Ampligen (rintatolimod), a drug of large macromolecular ribonucleic acid (RNA) molecules and Alferon N Injection (Interferon Alfa-N3). Ampligen is approved for commercial sale in the Argentine Republic for the treatment of severe chronic fatigue syndrome (CFS) and is an experimental drug in the United States undergoing clinical development for the treatment of certain cancers and ME/CFS. Alferon N Injection is the registered trademark for its injectable formulation of natural alpha interferon. Alferon N Injection is a natural-source, multi-species alpha interferon approved for sale in the United States and Argentina for the intralesional treatment of refractory or recurring external genital warts in patients 18 years of age or older.

Contact Information

Headquarters
2117 SW Highway 484OCALA, FL, United States 34473-7949
Phone
352-448-7797
Fax
352-480-4620

Executives

Independent Chairman of the Board
William Mitchell
President, Chief Executive Officer, Executive Vice Chairman
Thomas Equels
Chief Financial Officer
Robert Dickey
Chief Operating Officer, Executive Director - Governmental Relations, General Counsel, Secretary
Peter Rodino
Chief Scientific and Medical Officer
David Strayer

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals Table
Market Cap
$20.4M
Revenue (TTM)
$193.0K
Shares Outstanding
48.8M
Dividend Yield
0.00%
Annual Dividend Rate
---
Ex-Dividend Date
01-01-01
Pay Date
01-01-01
Beta
-0.11
EPS
$-0.43
Book Value
$0.80
P/E Ratio
-1.0x
Price/Sales (TTM)
105.7
Price/Cash Flow (TTM)
---
Operating Margin
-12,160.10%
*GAAP = prior to non-GAAP analyst adjusted earnings.

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.